BTG (BTG)

 

BTG Share PerformanceMore

52 week high739.5 12/07/16
52 week low504.0 10/11/15
52 week change -19.0 (-2.91%)
4 week volume10,552,193 04/09/16

Latest NewsMore

Holding(s) in Company

RNS Number: 0995L BTG PLC 28 September 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii BTG Plc. 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights Yes An acquisition or disposa...

Holding(s) in Company

Notification of major interests in shares

Director Deals - BTG PLC (BTG)

Rolf Soderstrom, Financial Director, exercised 3,108 shares in the company on the 1st September 2016 at a price of 289.49p. T...

Director Deals - BTG PLC (BTG)

Dr Louise Makin, Chief Executive Officer, exercised 1,243 shares in the company on the 1st September 2016 at a price of 28...

Director/PDMR Shareholding

How long can the hunt for yield continue?

Interest rates are falling and equity valuations keep rising, so what is an investor to do? Harriet Mann names the shares thi...

Total Voting Rights

Notification of a change in the total number of voting rights

Directorate Change

Notification of any change to a company’s board e.g. appointments/resignations/changes to important functions or executive responsibilities of a director

Fundamental DataMore

P/E ratio40.127
EPS15.8
Dividend yield0 %

Equity Research (BTG)

edison investment research
BTG plc
08/04/2016
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
edison investment research
BTG plc
30/11/2015
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
edison investment research
BTG plc
30/10/2015
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...

Latest discussion posts More

  • Re: Lets Play Guess The Bottom?

    No one picked up on this when I raised this. Importantly broke and held above fifty and two hundred day moving averages. Some analyst upgrades and strong buy recommendations ...
    17-Sep-2016
    sound money
  • Re: Class III CE Mark approval for DC Bead

    Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme's Lemtrada? (alemtuzumab) in Clinical Trials ...
    16-Sep-2016
    d gaser
  • Vaithena

    Does anyone have any views on Varithena as this seems to be the dragging force on the stock . Along with share dilution for the directors benefit
    14-Sep-2016
    up protherics

Users' HoldingsMore

Users who hold BTG also hold..
PZ CUSSONS26%
LLOYDS GRP.26%
ENT. ONE DI26%
GLAXOSMITHKLINE22%
NATIONAL GRID22%

Codes & Symbols

ISINGB0001001592
SymbolsBTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG